Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trialDebu Tripathy, Yen‐Shen Lu, Sara A. Hurvitz et al.|The Lancet Oncology|2018Cited by 1k
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumoursMark T. J. van Bussel, Jan H.M. Schellens, Ahmad Awada et al.|British Journal of Cancer|2020Cited by 127
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumorsIván Díaz-Padilla, Philippe L. Bédard|Investigational New Drugs|2013Cited by 56